Literature DB >> 23900624

Treatment strategy for cutaneous apocrine carcinoma.

Dai Ogata1, Yoshio Kiyohara, Shusuke Yoshikawa, Masako Kasami.   

Abstract

BACKGROUND: Cutaneous apocrine carcinoma (CAC) is a rare adnexal carcinoma with only scattered reports about long-term follow-up. The aim of this study is to demonstrate clinical findings in the prognosis of CAC and discuss the treatment procedure.
METHODS: The subjects were nine patients with a histological diagnosis of CAC who underwent wide excision and regional lymph node dissection as the initial treatment at Shizuoka Cancer Center Hospital. We examined the gender, age, site of involvement, additional treatment to prevent recurrence/metastasis, additional treatment after metastasis, and the follow-up data of the study patients. Then, we calculated the recurrence and 5-year (overall/recurrence-free) survival rates.
RESULTS: The men-to-women ratio was 8:1. The patients ranged in age from 47 to 81 years (median, 67 years). The primary lesion was in the axilla in five patients and in the vulva in the other four patients. The follow-up period ranged from 9 to 204 months (median, 44 months). The recurrence-free 5-year survival rate was 63 %, and the overall 5-year survival rate was 75 %.
CONCLUSIONS: We recommend wide local excision for a primary lesion and prophylactic regional lymph node dissection at initial therapy because of the high frequency of regional metastasis of CAC. Although CAC responds poorly to chemotherapy and radiotherapy, adjuvant radiotherapy may be used in advanced local or regional disease.

Entities:  

Mesh:

Year:  2013        PMID: 23900624     DOI: 10.1007/s10147-013-0594-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  3 in total

1.  Apocrine carcinoma of the axillae. Case report.

Authors:  L Neumann; J A Sørensen
Journal:  Scand J Plast Reconstr Surg Hand Surg       Date:  1989

2.  Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases.

Authors:  Alistair Robson; Alexander J F Lazar; Jara Ben Nagi; Andrew Hanby; Wayne Grayson; Meora Feinmesser; Scott R Granter; Paul Seed; Carla L Warneke; Phillip H McKee; Eduardo Calonje
Journal:  Am J Surg Pathol       Date:  2008-05       Impact factor: 6.394

3.  Apocrine carcinoma of the skin. A clinicopathologic, immunocytochemical, and ultrastructural study.

Authors:  C Paties; G L Taccagni; M Papotti; G Valente; A Zangrandi; F Aloi
Journal:  Cancer       Date:  1993-01-15       Impact factor: 6.860

  3 in total
  6 in total

Review 1.  Cutaneous apocrine carcinoma in groin with bilateral lymph node metastasis: a case report and review of the literature.

Authors:  Jingjing Guo; Gang Wu; Jinhua Xu; Zhenyu Ma; Zhongwen Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

2.  Surgery and Adjuvant Radiation for High-risk Skin Adnexal Carcinoma of the Head and Neck.

Authors:  Lora S Wang; Elizabeth A Handorf; Hong Wu; Jeffrey C Liu; Clifford S Perlis; Thomas J Galloway
Journal:  Am J Clin Oncol       Date:  2017-08       Impact factor: 2.339

3.  Rare malignant adnexal tumour of the skin involving distal phalanx of right thumb with co-existing primary lung cancer in a 72-year-old patient: A case report.

Authors:  Deepika Aggarwal; Vimal Jain
Journal:  Int J Surg Case Rep       Date:  2022-05-10

4.  Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.

Authors:  Rami Mäkelä; Ville Härmä; Nibal Badra Fajardo; Greg Wells; Zoi Lygerou; Olle Sangfelt; Juha Kononen; Juha K Rantala
Journal:  Oncotarget       Date:  2021-05-25

5.  Malignant adnexal tumors of the skin: a single institution experience.

Authors:  Tolutope Oyasiji; Wei Tan; John Kane; Joseph Skitzki; Valerie Francescutti; Kilian Salerno; Nikhil I Khushalani
Journal:  World J Surg Oncol       Date:  2018-05-30       Impact factor: 2.754

6.  Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective.

Authors:  Marcin Kleibert; Iga Płachta; Anna M Czarnecka; Mateusz J Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.